Organon & Co. (OGN) Covered Calls

Organon is a global healthcare company dedicated to improving the health of women throughout their lives. Spun off from Merck in 2021, the firm manages a diverse portfolio of prescription therapies across women’s health, biosimilars, and established brands. With a presence in over 140 markets, it focuses on delivering impactful medicines for reproductive health, fertility, and chronic conditions while leveraging its established brands to fund innovation in unmet medical needs.

You can sell covered calls on Organon & Co. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OGN (prices last updated Tue 4:16 PM ET):

Organon & Co. (OGN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
8.14 +0.22 8.01 8.14 4.7M 4.1 2.1
Covered Calls For Organon & Co. (OGN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Mar 20 7.5 0.75 7.39 1.5% 21.9%
Apr 17 7.5 0.95 7.19 4.3% 29.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Organon (OGN) operates as a specialized pharmaceutical leader with a primary focus on women’s health, supported by a significant portfolio of biosimilars and mature established brands. The company’s core business is built upon its leadership in reproductive health, featuring flagship products like Nexplanon, a long-acting reversible contraceptive, and a robust fertility franchise. By maintaining a vast international distribution network, the firm generates more than 75% of its revenue outside the United States, providing a diversified global cash flow base.

The company’s strategic model utilizes the steady cash flows from its established brands—covering therapeutic areas such as cardiovascular, respiratory, and dermatology—to invest in high-growth biosimilars and innovative women’s health solutions. This hybrid approach allows the firm to commercialize lower-cost alternatives to complex biologics while simultaneously developing new treatments for conditions like endometriosis and polycystic ovarian syndrome. Through this structure, the company seeks to address significant gaps in the global healthcare market specifically tailored to female patients.

Competitive Landscape

The pharmaceutical industry is characterized by intense regulatory scrutiny, patent expiries, and competition from both generic manufacturers and diversified healthcare giants. Organon competes for market share in the established medicines and biosimilars sectors with Viatris and Perrigo Company. In the broader specialty pharmaceutical and women’s health arena, it also faces competition from Bausch Health and its former parent company, Merck & Co.

While the company faces pressure from generic erosion in its mature portfolio, it differentiates itself through its "Women’s Health First" mission and its extensive expertise in long-acting reversible contraception. This specialization provides a competitive moat in markets where reproductive health remains a critical public health priority. Furthermore, its partnership-driven biosimilars strategy allows it to launch complex biologic alternatives with lower R&D risk than traditional drug discovery, positioning the firm as a high-efficiency commercialization engine in the global specialty medicine landscape.

Strategic Outlook and Innovation

Operational priorities are currently focused on the integration of Vtama, a novel non-steroidal topical treatment for psoriasis and atopic dermatitis acquired through the purchase of Dermavant Sciences. This expansion into medical dermatology represents a significant move to diversify revenue beyond core reproductive health and mitigate the impact of recent loss-of-exclusivity events. The company is also leveraging a newly signed exclusive license for MIUDELLA, a hormone-free copper IUD, to strengthen its long-term leadership in the U.S. contraceptive market by offering patients a wider variety of non-hormonal options.

Looking ahead, the company is prioritizing aggressive deleveraging, utilizing proceeds from the recent divestiture of the JADA System to reduce its debt-to-EBITDA ratio. Management is also executing a supply chain separation from Merck, which is expected to drive significant gross margin expansion starting in 2027 by reducing manufacturing and logistical overhead. These efficiency gains, combined with a focus on ex-U.S. growth for Nexplanon and the launch of new biosimilars like POHERDY, are intended to stabilize the company’s financial profile and fund a sustainable pipeline of treatments for the unique health challenges women face globally.